Prosecution Insights
Last updated: November 20, 2026

Heather Raquel Dahlin, USPTO Patent Examiner

Listed by the USPTO as DAHLIN, HEATHER RAQUEL

Tech Center 1600 • Art Units: 1628 1629

This examiner grants 42% of resolved cases

Analysis

DAHLIN, HEATHER RAQUEL is a USPTO patent examiner in Tech Center 1600 and Art Unit 1628. The record covers 168 resolved cases, with a 42.3% allowance rate and a median of 1233 days to allowance. Interviews are associated with a 46.6% lift, a substantial relationship within the reported outcomes.

The leading companies are Hoffmann-La Roche Inc., King's College London, and Peloton Therapeutics Inc. A Fully Owned Subsidiary Of Merck Sharp & Dohme LLC. The leading firms are BIRCH STEWART KOLASCH & BIRCH, LLP, NOVICK, KIM & LEE, PLLC, dba NKL Law, and OLIFF PLC. Counsel may want to treat interviews as an important part of prosecution planning while budgeting for a 1233-day median.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

42.3%
Allow Rate
-17.7% vs TC avg
231
Total Applications
+46.6%
Interview Lift
1233
Avg Prosecution Days
Based on 168 resolved cases, 2023–2026

Rejection Statute Breakdown

4.4%
§101 Eligibility
19.4%
§102 Novelty
35.0%
§103 Obviousness
25.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18823182 THERAPEUTIC COMPOUNDS AND METHODS OF USE Non-Final OA Genentech, Inc.
18255076 NEW INDAZOLE DERIVATIVES Final Rejection Hoffmann-La Roche Inc.
18730353 Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397) Non-Final OA AMGEN INC.
17622121 COMPOUNDS HAVING ANTIMALARIAL ACTIVITY Non-Final OA NANYANG TECHNOLOGICAL UNIVERSITY
18023211 KAEMPFEROL AGLYCONE-CONTAINING EXTRACT Final Rejection OTSUKA PHARMACEUTICAL CO., LTD.
18265335 COMPOSITIONS AND METHODS FOR INHIBITING M PRO PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-COV-2 INFECTION Final Rejection Arizona Board of Regents on Behalf of the University of Arizona
17993922 METHOD FOR SCREENING MARKERS FOR PREDICTING PROGNOSIS OF RENAL CELL CARCINOMA USING TRANSCRIPTOMIC ANALYSIS Non-Final OA Gwangju Institute of Science and Technology
18269526 COMBINATION THERAPY WITH A VINCA ALKALOID N-OXIDE AND AN IMMUNE CHECKPOINT INHIBITOR Non-Final OA CASCADE PRODRUG INC.
18514697 COMPOSITIONS AND METHODS FOR TREATMENT OF INSOMNIA Final Rejection Individual inventor

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Heather Raquel Dahlin's allowance rate?

42.3% of resolved applications examined by Heather Raquel Dahlin were allowed (168 resolved cases), compared with 25.9% across Art Unit 1628 over the last five years.

Does an interview help with examiner Heather Raquel Dahlin?

This examiner's interview lift is +46.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Heather Raquel Dahlin take to allow a patent?

Applications allowed by Heather Raquel Dahlin took 1,233 days on average from filing to allowance.

Which art unit does examiner Heather Raquel Dahlin work in?

Heather Raquel Dahlin examines applications in Art Unit 1628 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month